Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2017—Ortho Clinical Diagnostics announced that its Vitros Immunodiagnostic Products Insulin Reagent and Calibrators have received FDA clearance and the CE mark. The assay is expected to be commercially available for use on all of the company’s Vitros immunodiagnostic and integrated systems in Europe, in other countries accepting the CE mark, and in the U.S. during the third quarter of this year.
October 2017—The Clinical and Laboratory Standards Institute has published a microbiology guideline, “M58: Methods for the Identification of Cultured Microorganisms Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry, 1st ed.”
October 2017—Baebies, a Durham, NC–based company focused on advancing newborn screening and pediatric testing, has signed a bilateral distribution agreement with Trivitron’s Labsystems Diagnostics to deliver newborn screening solutions to several markets worldwide. Baebies will distribute Labsystems’ newborn screening products NeoMass AAAC and NS 2400 in the United States after obtaining regulatory clearance.
October 2017—Metabolon has acquired Metabolomic Discoveries, a metabolomics services and diagnostics company based near Berlin, Germany.
October 2017—Thermo Scientific Samco Clicktainer leakproof vials have been developed to provide sample protection and user safety by enabling correct cap application. The vials are designed for the secure collection and handling of fluid, solid, and powder samples, including urine, sputum, and stool specimens; the lid-lock design makes them ideal for the secure transport of clinical, research, and forensic samples.
October 2017—PerkinElmer is collaborating with In-Depth Genomics to support IDG’s whole genome sequencing diagnostic program, which will bring genetic diagnosis to patients who have a wide range of neurological conditions, including orphan disorders, and aims to provide improved diagnoses and treatments.
October 2017—Ambry Genetics and NorthShore University HealthSystem’s Center for Personalized Medicine (Evanston, Ill.) will partner to offer genetic testing and research to advance precision medicine in preventive care.
October 2017—Bio-Rad Laboratories announced FDA clearance for its BioPlex 2200 ToRC IgM Assay, a fully automated assay for the detection of IgM class antibodies to Toxoplasma gondii, rubella, and cytomegalovirus offered in a multiplexed panel.
October 2017—Morphotek, a subsidiary of Eisai, has entered into a collaboration and license agreement with Fujirebio Diagnostics to validate and commercialize the CA125 II assay for use on the Lumipulse system as a companion diagnostic to aid in the selection of ovarian cancer patients who may best respond to farletuzumab.
October 2017—TechLab received FDA clearance for the Tri-Combo Parasite Screen test. The test is an enzyme immunoassay for the simultaneous qualitative detection of Giardia spp., Cryptosporidium spp., and/or E. histolytica antigen in human fecal specimens. It specifically detects pathogenic E. histolytica and does not cross-react with nonpathogenic E. dispar.
